-+ 0.00%
-+ 0.00%
-+ 0.00%

Vanda’s Nereus reduces semaglutide-induced vomiting by 27% in Phase III trial

PUBT·10/27/2026 10:52:09
Vanda’s Nereus reduces semaglutide-induced vomiting by 27% in Phase III trial
  • Vanda Pharmaceuticals announced positive Phase III results for Nereus (tradipitant) to prevent vomiting associated with GLP-1 therapy.
  • The treatment significantly reduced vomiting versus placebo, including frequent multiday and extreme vomiting.
  • No new safety signals emerged; the treatment was generally well tolerated.
  • Vanda plans FDA discussions and a supplemental New Drug Application seeking the additional use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610270650PR_NEWS_USPR_____PH81664) on October 27, 2026, and is solely responsible for the information contained therein.